Pharmafile Logo
Pharmafocus logo
Advanced Search

UC San Diego School of Medicine researchers treat atopic dermatitis with bacteriotherapy

February 24, 2021
Research and Development atopic dermatitis, eczema

Researchers at the University of California San Diego School of Medicine have identified a universal strain of bacteria derived from …

News

Sanofi and SIRION collaborate on AAV vector development to treat serious diseases

February 24, 2021
Research and Development AAV vectors, SIRION, Sanofi

SIRION Biotech and Sanofi have entered into an agreement to develop effective medicines for illnesses impacting major human organs.

News
cervical dysplasia

QIAGEN and INOVIO to develop diagnostic tests for cervical dysplasia treatment

February 24, 2021
Research and Development Inovio, Qiagen, cervical dysplasia

QIAGEN and INOVIO Pharmaceuticals have extended their collaboration to develop a new diagnostic test which identifies the women most likely …

News
bluebird_bio_external_durham_nc_manufacturing

FDA halts studies for bluebird bio’s sickle cell therapy LentiGlobin

February 24, 2021
Research and Development Bluebird Bio, FDA, sickle cell disease

The FDA has put bluebird bio’s LentiGlobin gene therapy programme for sickle cell disease (SCD) on clinical hold, following Suspected …

News
opaganib-bottle-and-tablets

RedHill Biopharma to expand COVID-19 opaganib trial to US

February 24, 2021
Research and Development COVID-19, RedHill Biopharma

RedHill Biopharma has announced its plans to expand the company’s global Phase II/III study of opaganib in patients with severe …

News

Microsoft and UCB collaborate to treat immunological and neurological diseases

February 23, 2021
Manufacturing and Production Microsoft, UCB, artificial intelligence

UCB and Microsoft have agreed a new multi-year collaboration to discover new medicines by combining UCB’s drug discovery and development …

News

Otonomy’s OTIVIDEX ear medicine falls short in Phase III study

February 23, 2021
Manufacturing and Production meniere's disease, otividex, otonomy

Otonomy’s OTIVIDEX treatment for Meniere’s disease has failed to meet its primary endpoint in its Phase III trial, the company …

News

Novo Holdings acquires pharma research company Altasciences

February 23, 2021
Manufacturing and Production Novo Holdings, altasciences, pharma research

Novo Holdings has agreed a deal to buy Canadian pharmaceutical research company Altasciences from Audax Private Equity, the two companies …

News
dynavax

Dynavax’s hepatitis B vaccine gets EU approval

February 23, 2021
Manufacturing and Production EU, Vaccine, hepatitis B

The European Commission (EC) has granted marketing authorisation Dynavax Technologies Corporation’s HEPLISAV B vaccine for the active immunisation against hepatitis …

News
libtayo

FDA approves Regeneron & Sanofi’s Libtayo for advanced non-small cell lung cancer

February 23, 2021
Manufacturing and Production Cancer, Sanofi

The FDA has approved Regeneron & Sanofi’s PD-1 inhibitor Libtayo (cemiplimab-rwlc) for the first-line treatment of patients with advanced non-small …

News

GSK and Sanofi to begin new Phase II trial of their COVID-19 vaccine

February 22, 2021
Sales and Marketing COVID, COVID Vaccine, COVID-19, GSK, Sanofi

GlaxoSmithKline (GSK) and Sanofi are set to begin a new Phase II study of their COVID-19 vaccine candidate, following setbacks …

News

ONK and Anthony Nolan combine forces to work on blood cancer therapies

February 22, 2021
Sales and Marketing Anthony Nolan, Cancer, ONK, blood cancer, cancer treatment

ONK Therapeutics and blood cancer charity Anthony Nolan will work together on therapies for patients with haematological malignancies (blood cancers) …

News
minaris-mg_7425-web

MaxiVAX and Minaris sign manufacturing deal for cell-based cancer immunotherapy

February 22, 2021
Sales and Marketing Cancer, MaxiVAX, Minaris

MaxiVAX and Minaris Regenerative Medicine have entered into a manufacturing agreement for MVX-ONCO-2, a cell-based immunotherapy for the treatment of …

News
astrazeneca_plaque

AstraZeneca to withdraw Imfinzi US indication for bladder cancer

February 22, 2021
Sales and Marketing AstraZeneca, Imfinzi

AstraZeneca will voluntarily withdraw the Imfinzi (durvalumab) indication in the US for previously treated adult patients with locally advanced or …

News
tukysa

Seagen’s breast cancer drug TUKYSA gets UK approval

February 22, 2021
Sales and Marketing Cancer, MHRA, Seagen

The MHRA has granted marketing authorisation in the UK for Seagen’s TUKYSA (tucatinib) in combination with trastuzumab and capecitabine, for …

News
top 10

Pharmafile.com’s top 10 news stories of the week

February 19, 2021
Medical Communications COVID-19, COVID-19 vaccine, Vaccine, pharma news, top 10, top news stories

In the last week, a number of COVID-19 new vaccine developments have been made. Pfizer and BioNTech’s vaccine has proven …

News

New Cell Guidance technology has potential to help treat cancer

February 19, 2021
Medical Communications Cancer, cancer treatment, cell guidance systems, macrophages, pharma news

Cell Guidance Systems’ new POlyhedrin Delivery System (PODS) technology has been shown to have therapeutic potential in the treatment of …

News
cascade_chemistry_new_facility_rendering_highres

Cascade Chemistry begins $14m manufacturing facility expansion

February 19, 2021
Medical Communications Cascade Chemistry, manufacturing

Cascade Chemistry, a leading pharmaceutical contract development and manufacturing organisation, has initiated the $14 million construction of new facilities to …

News
cream-4713579_1920

Dermavant announces positive Phase III findings for psoriasis treatment tapinarof

February 19, 2021
Medical Communications Dermavant Sciences, psoriasis

Dermavant Sciences has announced positive safety and efficacy results from a planned interim analysis of PSOARING 3, a long-term, open-label …

News

RedHill enters manufacturing deal with Cosmo for two key products

February 19, 2021
Medical Communications RedHill Biopharma

RedHill Biopharma has announced agreements with Cosmo Pharmaceuticals to manufacture two of RedHill’s key products. Cosmo will manufacture Movantik, RedHill’s …

News
The Gateway to Local Adoption Series

Latest content

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance

January 27, 2026

Crystalys Therapeutics appoints Justin Thacker as Chief Financial Officer

January 27, 2026

Rentschler Biopharma appoints Uwe Buecheler as interim CEO

January 26, 2026

Sandoz’ Ondibta receives European Commission approval for diabetes

January 26, 2026

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026